(1, 3)-β-D-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies

Oncotarget

Volumn 7, Issue 16, 2016, Pages 21484-21495

  Azoulay, Elie ^a   Guigue, Nicolas ^a   Darmon, Michael ^b   Mokart, Djamel ^c   Lemiale, Virginie ^a   Kouatchet, Achille ^d   Mayaux, Julien ^e   Vincent, François ^f   Nyunga, Martine ^a   Bruneel, Fabrice ^a   Rabbat, Antoine ^g   Bretagne, Stéphane ^a   Lebert, Christine ^h   Meert, Anne Pascale ⁱ   Benoit, Dominique ^j   Pene, Frédéric ^g  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

^c Medical Surgical ICU Paoli Calmette Cancer Institute   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f Montfermeil Hospital   (France)

^g Institut Cochin   (France)

^h La Roche sur Yon Hospital   (France)

ⁱ JULES BORDET INSTITUTE   (Belgium)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

(1 3) beta D glucan assay; Diagnostic tests; Intensive care units; Invasive fungal infection

Indexed keywords

1,3 BETA DEXTRO GLUCAN; BIOLOGICAL MARKER; GLUCAN; UNCLASSIFIED DRUG; BETA GLUCAN; BETA-1,3-D-GLUCAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BG ASSAY; BIOASSAY; CANDIDEMIA; COMORBIDITY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FUSARIOSIS; HEMATOLOGIC MALIGNANCY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PREDICTIVE VALUE; PREVALENCE; SENSITIVITY AND SPECIFICITY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SYSTEMIC MYCOSIS; BLOOD; COMPLICATION; CRITICAL ILLNESS; HEMATOLOGIC DISEASE; HOSPITAL MORTALITY; LENGTH OF STAY; MIDDLE AGED; MORTALITY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADULT; BETA-GLUCANS; BIOMARKERS; CRITICAL ILLNESS; FEMALE; HEMATOLOGIC NEOPLASMS; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; INVASIVE FUNGAL INFECTIONS; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 84965046321     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7471     Document Type: Article

References (30)

1. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
2. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265-73.
3. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad, II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of A. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56-93
4. Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J, Vincent F, Nyunga M, Bruneel F, Laisne LM, Rabbat A, Lebert C, Perez P, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium-a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol 2013; 31: 2810-8
5. Azoulay E, Mokart D, Lambert J, Lemiale V, Rabbat A, Kouatchet A, Vincent F, Gruson D, Bruneel F, Epinette-Branche G, Lafabrie A, Hamidfar-Roy R, Cracco C, et al. Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. Am J Respir Crit Care Med 2010; 182:1038-46
6. Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, Rex JH, Ostrosky-Zeichner L: Prospective survey of (1→ 3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 2011; 49:58-61.
7. Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A: Elevation of blood (1→ 3)-beta-D-glucan concentrations in hemodialysis patients. Nephron 2001; 89: 15-9.
8. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S: ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012; 47: 846-54.
9. Obayashi T, Yoshida M, Tamura H, Aketagawa J, Tanaka S, Kawai T: Determination of plasma (1→3)-beta-D-glucan: a new diagnostic aid to deep mycosis. J Med Vet Mycol 1992; 30: 275-80.
10. Obayashi T, Negishi K, Suzuki T, Funata N: Reappraisal of the serum (1→3)-beta-D-glucan assay for the diagnosis of invasive fungal infections-a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46: 1864-70.
11. Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, Reitzel R, Raad I: Utility of galactomannan enzyme immunoassay and (1, 3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 2009; 47: 129-33.
12. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, SchiffR, Tamura H, Finkelman MA, Rex JH: Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-9.
13. Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2008; 46:1009-13.
14. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoffdevelopment, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
15. Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, Matsuura S, Duvoisin B, Bille J, Calandra T, Marchetti O. 1, 3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46: 878-85.
16. De Vlieger G, Lagrou K, Maertens J, Verbeken E, Meersseman W, Van Wijngaerden E, Obayashi T, Negishi K, Suzuki T, Funata N. Beta-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based study Reappraisal of the serum (1→3)-beta-D-glucan assay for the diagnosis of invasive fungal infections-a study based on autopsy cases from 6 years. J Clin Microbiol 2011; 49:3783-7.
17. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011; 52:750-70.
18. Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, Marchetti O. beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012; 54:633-43.
19. Maschmeyer G, Carratala J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M, Salwender H, Schmidt-Hieber M, Azoulay E. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 2014; 26:21-33.
20. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-10.
21. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39:165-228.
22. Azoulay E, Lemiale V, Mokart D, Pene F, Kouatchet A, Perez P, Vincent F, Mayaux J, Benoit D, Bruneel F, Meert AP, Nyunga M, Rabbat A, et al. Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med 2014; 40:1106-14.
23. Hernu R, Wallet F, Thiolliere F, Martin O, Richard JC, Schmitt Z, Wallon G, Delannoy B, Rimmele T, Demaret C, Magnin C, Vallin H, Lepape A, et al. An attempt to validate the modification of the American-European consensus definition of acute lung injury/acute respiratory distress syndrome by the Berlin definition in a university hospital. Intensive Care Med 2013; 39: 2161-70.
24. Mokart D, Darmon M, Resche-Rigon M, Lemiale V, Pene F, Mayaux J, Rabbat A, Kouatchet A, Vincent F, Nyunga M, Bruneel F, Lebert C, Perez P, et al. Prognosis of neutropenic patients admitted to the intensive care unit. Intensive Care Med 2015; 41:296-303.
25. Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, WolffM, Fontanet A, Bretagne S, Dromer F. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med 2014; 40:1303-12.
26. Albert O, Toubas D, Strady C, Cousson J, Delmas C, Vernet V, Villena I: Reactivity of (1→3)-beta-d-glucan assay in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis 2011; 30:1453-60.
27. Leone M, Bechis C, Baumstarck K, Lefrant JY, Albanese J, Jaber S, Lepape A, Constantin JM, Papazian L, Bruder N, Allaouchiche B, Bezulier K, Antonini F, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014; 40:1399-408.
28. Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernandez-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Marquez-Vacaro JA. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40: 32-40.
29. Mokart D, Slehofer G, Lambert J, Sannini A, Chow-Chine L, Brun JP, Berger P, Duran S, Faucher M, Blache JL, Saillard C, Vey N, Leone M. De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Med 2014; 40:41-9.
30. Sharma S, Nadrous HF, Peters SG, Tefferi A, Litzow MR, Aubry MC, Afessa B. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 2005; 128:1385-92.